Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Altamira Therapeutics (OTCQB: CYTOF), a company focused on RNA delivery technology development for targets beyond the liver, has scheduled its Full Year 2024 Financial Results and Business Update Call for April 30, 2025, at 8:00 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altamira Therapeutics (OTCQB: CYTOF), a company focused on RNA delivery technology development for targets beyond the liver, has scheduled its Full Year 2024 Financial Results and Business Update Call for April 30, 2025, at 8:00 am ET.
The presentation will feature prepared remarks from Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda. The call will be conducted in listen-only mode, with replay access available through the webcast link after the live event.
Details
News Market Reaction – CYTOF
The recorded move for CYTOF in the trading session of this news was -9.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hamilton, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Full Year 2024 Financial Results and Business Update Call on Wednesday, April 30, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Webcast Access:
- Event: Altamira Therapeutics Full Year 2024 Financial Results and Business Update Call
- Date: Wednesday, April 30, 2025
- Time: 8:00 am ET
- Webcast URL: https://edge.media-server.com/mmc/p/7t3h98aw
Registration for Call:
https://register-conf.media-server.com/register/BI95acee4618c44d05a56b78125b22638d
- Click on the call link and complete the online registration form.
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call.
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
The call will be in listen-only mode.
A replay of the call will be available after the live event and accessible through the webcast link:
https://edge.media-server.com/mmc/p/7t3h98aw
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Investor Contact
Hear@altamiratherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.